Comparison of whole-cell versus acellular pertussis vaccine effectiveness in school clusters of pertussis, France, 2013 - 22/09/20
, S. Guillot b, I. Poujol c, A. Thabuis c, L. Chouin d, M. Martel e, E. Delisle f, C. Six g, N. Guiso b, D. Lévy-Bruhl aBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 3 |
| Iconographies | 0 |
| Vidéos | 0 |
| Autres | 0 |
Highlights |
• | In 2013, the French national agency for public health (Santé publique France) and its regional units performed a prospective study to compare the effectiveness and protection duration of whole-cell versus acellular pertussis vaccines. |
• | Seven investigations of epidemic clusters in a cohort of 305 school children from the 2nd grade to the 6th grade resulted in the identification of 102 clinical cases of pertussis, including 10 cases biologically confirmed by Bordetella pertussis specific PCR. |
• | The risk of pertussis when vaccinated with an acellular vaccine alone was 1.6 (RR=1.6; 95% CI=1.1–2.5) times higher than when vaccinated with a whole-cell vaccine or using a combined schedule. |
• | The limited duration of protection conferred by the acellular vaccine is in favor of the introduction of the pertussis booster for 6-year-old children in 2013. |
Abstract |
Objectives and method |
We conducted a prospective study in 2013 to compare the whole-cell versus acellular pertussis vaccines effectiveness and duration of protection, following the occurrence of pertussis clusters.
Results |
During seven school outbreaks, we identified 102 clinical pertussis cases, including 10 cases biologically confirmed by Bordetella pertussis specific PCR, among a cohort of 305 children in 2nd to 6th grade. The risk of pertussis when vaccinated with an acellular vaccine alone was 1.6 (RR=1.6; 95% CI=1.1–2.5) times higher than when vaccinated with a whole-cell vaccine or using a combined schedule.
Conclusions |
The limited duration of protection conferred by the acellular vaccine reinforces the 2013 introduction of the pertussis booster at six years old.
Le texte complet de cet article est disponible en PDF.Keywords : Pertussis, Vaccine effectiveness, School outbreaks, Whole-cell pertussis vaccine, Acellular pertussis vaccine
Plan
Vol 50 - N° 7
P. 617-619 - octobre 2020 Retour au numéro
Article précédent
- Fosfomycin, from susceptibility to resistance: Impact of the new guidelines on breakpoints
- E. Farfour, N. Degand, E. Riverain, V. Fihman, C. Le Brun, G. Péan de Ponfilly, A. Muggeo, A. Jousset, C. Piau, P. Lesprit, The GMC study group, N. Chatelain, L. Dortet, A. Poisson, T. Guillard, A. Limelette, A. Mizrahi, A. Le Monnier, D. Fournier, A. Potron, P. Morand, F. Janvier, M.-P. Otto, P.-L. Woerther, J.-W. Decousser, S. Corvec, C. Plouzeau-Jayle, L. Broutin, N. Yin, G. Héry-Arnaud, C. Beauruelle, A. Grillon, M. Lecuru, E. Bille, S. Godreuil, H. Jean Pierre, M. Amara, A. Henry, J.-R. Zahar, E. Carbonelle, F. Jaureguy, A. Lomont, C. Isnard, V. Cattoir, F. Canis, T. Diedrich, E. Flevin, A. Merens, H. Jacquier, E. Gyde
- Infection d’endoprothèse aortique à Coxiella burnetii
- A. Hamon, F. El Sayed, F. Bouchand, B. Davido, C. Duran, M. Coggia, I. Javerliat, A. Dinh
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?